title: [Preparation of nosiheptide liposomes and its inhibitory effect on hepatitics B virus in vitro].
abstract: OBJECTIVE
  To prepare liposomes of nosiheptide and study its ability to inhibit hepatitis B virus HBsAg and HBeAg secreted.
  
  
  METHODS
  Liposomes of nosiheptide was prepared by sodium deoxycholate dialysis and sonication. Nosheptide was determined by HPLC and partical size was determined by using laser light scattering instrument. Transmission electron microscopy (TEM) was used to examine the morphology of liposomes. Its actions to inhibit hepatitis B virus HBsAg and HBeAg secreted was studied by a HBV-transfectted cell line (HepG2 2. 2. 15 ).
  
  
  RESULTS
  Encapsulation efficiency of liposomes by chloroform:methanol (2:1, v/v) was higher than that by dioxane. With the increase of the ratio of nosiheptide: PC (W/W), the encapsulation efficiency of liposomes decreased with the increase of ratio of sodium deoxycholate: PC, the liposomes partical size decreased. The liposomes kept stable at -20 degrees C after 2 years. The drug concentrations of liposomes that inhibit HBsAg secreted by (46.9 +/- 2. 6) %, (55.4 +/- 1.2) %, (65 +/- 3) % and HBeAg secreted by (15.1 +/- 2.3) %, (36.2 +/- 1.7) %, (36.8 +/- 2.5) % were 1.25, 2.5, 5.0 microg x mL(-1), respectively.
  
  
  CONCLUSIONS
  Liposomes of nosheptide can be prepared by sodium deoxycholate dialysis and sonication, which ability to inhibit hepatitis B virus HBsAg and HBeAg secreted is better than nosheptide.
authors.affiliation: School of Pharmacy, Fudan University, Shanghai 200032, China.
authors.forename: Qin-sheng
authors.initials: QS
authors.lastname: Cai
authors.forename: Hai
authors.initials: H
authors.lastname: Huang
authors.forename: Mei-qing
authors.initials: MQ
authors.lastname: Feng
authors.forename: Pei
authors.initials: P
authors.lastname: Zhou
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage* / Q000494:pharmacology; D045744:Cell Line, Tumor; D004337:Drug Carriers; D004339:Drug Compounding; D016503:Drug Delivery Systems; D004355:Drug Stability; D006514:Hepatitis B Surface Antigens / Q000187:drug effects; D006513:Hepatitis B e Antigens / Q000187:drug effects; D006515:Hepatitis B virus / Q000187:drug effects* / Q000276:immunology; D018197:Hepatoblastoma / Q000821:virology; D006801:Humans; D008081:Liposomes; D008113:Liver Neoplasms / Q000821:virology; D010316:Particle Size; D013844:Thiazoles / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D000998:Antiviral Agents; D004337:Drug Carriers; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D008081:Liposomes; D013844:Thiazoles; C014134:nosiheptide